Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy
Sicherheit, Wirksamkeit und Doxorubicin-Pharmakokinetik unter cannabidiol-/cannabidiolsäurereichem Hanföl bei Hunden mit Lymphom unter CHOP-Chemotherapie
Journal of Veterinary Internal Medicine · 2025-07-01 · 39 (4)
DOI: 10.1111/jvim.70179 ↗Auf einen Blick
Bei 25 Hunden mit hochgradigem Lymphom war CBD/CBDA-reiches Hanföl während eines CHOP-Zyklus gut verträglich. Die Doxorubicin-Exposition unterschied sich im Verlauf nicht signifikant.
Fragestellung
Wie sicher und verträglich ist orales CBD/CBDA-reiches Hanföl bei Hunden mit hochgradigem Lymphom unter CHOP-Chemotherapie, und beeinflusst es die Doxorubicin-Exposition?
Methode
Prospektive, doppelblinde, randomisierte, placebokontrollierte Studie; orale CBD/CBDA-reiche Hanföl-Kapseln oder Placebo während eines CHOP-Zyklus.
Ergebnisse
25 Hunde eingeschlossen, 19 schlossen die Studie ab. Keine schweren unerwünschten Ereignisse; keine signifikanten Unterschiede bei hämatologischen/biochemischen Werten oder der Lebensqualität. Doxorubicin-AUC Woche 0: 390,8 vs. 403,4 nM/h; Woche 5: 572,6 vs. 406,8 nM/h.
Schlussfolgerung der Autor:innen
Kurzfristige orale CBD/CBDA-reiche Hanfsupplementierung schien bei Hunden unter CHOP-Chemotherapie für Lymphom sicher und gut verträglich.
Kernaussagen
- 25 Hunde, 19 mit Abschluss der Studie
- Keine schweren unerwünschten Ereignisse berichtet
- Doxorubicin-AUC unterschied sich im Verlauf nicht signifikant
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in Journal of Veterinary Internal Medicine, published online on 2025-07-01. Written by Amandine Lejeune and 5 co-authors. Institution: Department of Surgical and Radiological Sciences, University of California, School of Veterinary Medicine, Davis, California, USA. Major MEDLINE topics: Antineoplastic Combined Chemotherapy Protocols, Cannabidiol, Dog Diseases, Doxorubicin. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Onkologische Pflege
Abstract (original language)
Background
The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated.
Objectives
To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA-rich hemp oil supplementation in dogs diagnosed with high grade lymphoma undergoing CHOP chemotherapy. Animals Client-owned dogs diagnosed with lymphoma.
Methods
Dogs were enrolled in this prospective, double-blinded, randomized, placebo-controlled clinical trial to receive either CBD/CBDA-rich hemp oil capsules or placebo during one cycle of CHOP chemotherapy. Primary outcomes evaluated included adverse events during chemotherapy, quality of life scores and doxorubicin area under the curve (AUC) over a 5-week period.
Results
Twenty-five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6–479.4); CBD/CBDA 403.4 nM/h (351.9–462.5)] but was different at week 5 [placebo 572.6 (448.3–731.2); CBD/CBDA 406.8 (3.23.2–551.8)]. CBD/CBDA supplementation was well-tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences. Conclusion and Clinical Importance Short-term oral CBD/CBDA-rich hemp supplementation appeared safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgical and Radiological Sciences, University of California, School of Veterinary Medicine, Davis, California, USA.
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, Florida, USA.
- Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
- Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
ORCID profiles: Amandine Lejeune, Sandra Bechtel, Rowan Milner
Cite
APA
Lejeune, A., Bechtel, S., Milner, R., Fagman, L., Leal Yepes, F. A., & Wakshlag, J. J. (2025). Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy. Journal of Veterinary Internal Medicine, 39(4). https://doi.org/10.1111/jvim.70179
Vancouver
Lejeune A, Bechtel S, Milner R, Fagman L, Leal Yepes FA, Wakshlag JJ. Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy. Journal of Veterinary Internal Medicine. 2025;39(4). doi:10.1111/jvim.70179
BibTeX
@article{Lejeune2025,
author = {Lejeune, Amandine and Bechtel, Sandra and Milner, Rowan and Fagman, Lana and Leal Yepes, Francisco A and Wakshlag, Joseph J},
title = {Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
volume = {39},
number = {4},
doi = {10.1111/jvim.70179}
}
EUVIMED